Olivier Pasquier Joins CYTOO as Chief Commercial Officer
News Mar 18, 2013
Former Senior Marketing Manager Europe at QIAGEN, with more than 10 years experience in biology and biotechnology, he is passionate about biotech breakthroughs. He joins the team to lead the commercial success of CYTOO's 2D+ Cell Culture Platform and develop new markets in cell based assays and screening.
François Chatelain, CEO of CYTOO, says “We're delighted to welcome Olivier at CYTOO: I have no doubt that his insights, energy and business initiatives will be really impactful on CYTOO’s development!"
“It is an honour for me to join the executive team of CYTOO”, says Olivier Pasquier. “This company has a unique talented team, a breakthrough technology, a secured financial background, able to deeply change the game in the cell-based assay science. I want to make sure that every lab using cell culture in the world accesses micropatterns and scientific expertise available at CYTOO.”
Tapeworm Drug Molecule Could Aid Fight Against Parkinson’s DiseaseNews
Researchers have identified a drug molecule within a medicine used to treat tapeworm infections which could lead to new treatments for patients with Parkinson's disease.READ MORE
IDEX Health & Science Announces Acquisition of New Microfluidics CompanyNews
IDEX Health & Science, LLC announced the acquisition of thinXXS Microtechnology that will accelerate growth of its microfluidics consumables business.READ MORE
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE